prices of glp 1 drugs Costly GLP-1 are Rarely Covered for Weight Loss by Marketplace Plans Direct-To-Consumer Drug Portals Offer Lower
Description
In a statement, the Danish company said the move would help to address "access barriers" to the medicines and "make it easier and more affordable for people in the US to get authentic, FDA-approved Wegovy and Ozempic in the way that best fits their lives." There's little doubt that one of the reasons for the move will be to try to keep pace with arch-rival Eli Lilly in the market for incretin-based therapies for obesity and T2D, particularly the strong growth of Lilly's dual GIP/GLP-1 agonist tirzepatide, whose growth rate is outstripping Novo Nordisk's products
doi: 10.1016/j.nlm.2010.02.002 56 BenedictCHallschmidMHatkeASchultesBFehmHLBornJet al
Over time, this can lead to weight loss
Pancreatic alpha- and beta-cell responses to GIP infusion in normal man
So thats one of the primary reasons, is the cost
GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity [1]
